The total prostate cancer treatment device market is expected to grow at double-digit rates over the forecast period, primarily driven by sales of robotic prostatectomy and EBRT capital equipment.
Vancouver, BC (PRWEB) January 25, 2012
According to a new report by iData Research (http://www.idataresearch.net), the leading global authority in medical device market research, the U.S. urological device market was valued at over $3.5 billion in 2011 and is expected to reach almost $6 billion by 2018. The fastest-growing segment in the urological device market in 2011 was the market for prostate cancer treatment devices, which includes brachytherapy, cryotherapy, robotic prostatectomy and external beam radiation therapy (EBRT). Growth in the urological device market will further be fueled by sales of intermittent urinary catheters and urological endoscopes.
“The total prostate cancer treatment device market is expected to grow at double-digit rates over the forecast period, primarily driven by sales of robotic prostatectomy and EBRT capital equipment,” says Dr. Kamran Zamanian, CEO of iData. “Not only is the incidence of prostate cancer increasing but the procedure of robotic prostatectomy has been gaining acceptance by urologists, due to their clinical benefits over traditional methods.”
The report states that external beam radiation therapy was the most popular procedure performed on patients diagnosed with prostate cancer in 2011, accounting for almost 80% of the total number of procedures performed that year. Robotic prostatectomy, however, grew at double-digit rates and is expected to continue to see strong growth through 2018. Within the prostate cancer treatment market, Intuitive Surgical monopolized robotic prostatectomy with their daVinci® surgical system, while Varian Medical Systems and Siemens dominated the external beam radiation therapy market, and C.R. Bard dominated the Brachytherapy market.
Additionally, the intermittent catheter market is set to continue its double digit growth through 2018 with Coloplast, C.R. Bard and Covidien battling for control of this segment.
“The significant increase in intermittent catheter sales can be contributed to changes made by the Centers for Medicare and Medicaid Services (CMS) for the reimbursement of intermittent urinary catheters, as well as the growing demand for hydrophilic-coated catheters,” says Dr. Zamanian. “These factors have caused the total urinary intermittent catheter market to grow significantly in the past year.”
For more information, register free on iData’s website at: http://www.idataresearch.net/idata/registration.php
iData’s 3-report series on the: “Markets for Urological Devices 2012” covers the U.S., Europe and Asia-Pacific regions and provides a comprehensive analysis on devices used in the treatment of benign prostate hyperplasia (BPH), prostate cancer, urinary incontinence as well as urinary and kidney stones. Other markets analyzed include bladder cancer fulguration, urodynamic equipment and nephrostomy devices.
About iData Research
iData Research (http://www.idataresearch.net/idata/discoveridata.php) is an international market research and consulting group focused on providing market intelligence for medical device, dental and pharmaceutical companies. iData covers research in: urology, endoscopy, laparoscopy, Women’s Health, ENT and more.
# # #